{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:53:39Z","timestamp":1791078819752,"version":"4.1.0"},"reference-count":86,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T00:00:00Z","timestamp":1526947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Efavirenz (EFV) and rifampicin\u2013isoniazid (RH) are cornerstone drugs in human immunodeficiency virus (HIV)\u2013tuberculosis (TB) coinfection treatment but with complex drug interactions, efficacy and safety challenges. We reviewed recent data on EFV and RH interaction in TB\/HIV high\u2010burden countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a systematic review of studies conducted in the high TB\/HIV\u2010burden countries between 1990 and 2016 on EFV pharmacokinetics during RH coadministration in coinfected patients. Two reviewers conducted article screening and data collection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 119 records retrieved, 22 were included (two conducted in children), reporting either EFV mid\u2010dose or pre\u2010dose concentrations. In 19 studies, median or mean concentrations of RH range between 1000 and 4000\u00a0ng\u00a0ml<jats:sup>\u20131<\/jats:sup>, the so\u2010called therapeutic range. The proportion of patients with subtherapeutic concentration of RH ranged between 3.1 and 72.2%, in 12 studies including one conducted in children. The proportion of patients with supratherapeutic concentration ranged from 19.6 to 48.0% in six adult studies and one child study. Five of eight studies reported virological suppression &gt;80%. The association between any grade hepatic and central nervous system adverse effects with EFV\/RH interaction was demonstrated in two and three studies, respectively. The frequency of the <jats:italic>CYP2B6 516G\u00a0&gt;\u00a0T<\/jats:italic> polymorphism ranged from 10 to 28% and was associated with higher plasma EFV concentrations, irrespective of ethnicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Anti\u2010TB drug coadministration minimally affect the EFV exposure, efficacy and safety among TB\u2010HIV coinfected African and Asian patients. This supports the current 600\u00a0mg EFV dosing when coadministered with anti\u2010TB drugs.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13600","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T22:54:28Z","timestamp":1523055268000},"page":"1641-1658","source":"Crossref","is-referenced-by-count":28,"title":["Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review"],"prefix":"10.1111","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3373-1999","authenticated-orcid":false,"given":"Daniel","family":"Atwine","sequence":"first","affiliation":[{"name":"Epicentre Mbarara Research Centre  Mbarara Uganda"},{"name":"Mbarara University of Science and Technology  Mbarara Uganda"},{"name":"University of Montpellier  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryline","family":"Bonnet","sequence":"additional","affiliation":[{"name":"Epicentre Mbarara Research Centre  Mbarara Uganda"},{"name":"IRD UMI233 TransVIHMI\u2010INSERM U1175  Montpellier France"},{"name":"University of Montpellier  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2010Marie","family":"Taburet","sequence":"additional","affiliation":[{"name":"Bicetre hospital  Paris France"},{"name":"UMR 1184, INSERM, CEA, Universit\u00e9 Paris\u2010Sud"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,22]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"World Health Organization.Global Health Observatory (GHO) data: HIV\/AIDS global situation and trends 2016. Available athttp:\/\/www.who.int\/gho\/hiv\/en\/(last accessed 13 July 2017)."},{"key":"e_1_2_7_3_1","unstructured":"World Health Organization.Tuberculosis and HIV 2014. Available athttp:\/\/www.who.int\/hiv\/topics\/tb\/about_tb\/en\/(last accessed 12 July 2017)."},{"key":"e_1_2_7_4_1","unstructured":"World Health Organization.Global tuberculosis report. Geneva2016. Available athttp:\/\/www.who.int\/tb\/publications\/global_report\/en\/(last accessed 21 June 2017)."},{"key":"e_1_2_7_5_1","unstructured":"World Health Organization.Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach Geneva2016. 2nd Available athttp:\/\/apps.who.int\/iris\/bitstream\/10665\/208825\/1\/9789241549684_eng.pdf(last accessed 29 July 2017)."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000239"},{"key":"e_1_2_7_7_1","unstructured":"AIDSinfo.Guidelines for the use of antiretroviral agents in HIV\u20101\u2010infected adults and adolescents.2016[updated 28th January 2016; cited 2016 01\/02]."},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031772"},{"key":"e_1_2_7_9_1","unstructured":"Anon.March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach.2013."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835f1db0"},{"key":"e_1_2_7_11_1","unstructured":"Clinton Health Access Initiative (CHAI).ARV market report: the state of the antiretroviral drug market in low\u2010 and middle\u2010income countries 2014\u20102019.2015. Available athttp:\/\/www.clintonhealthaccess.org\/content\/uploads\/2015\/11\/CHAI\u2010ARV\u2010Market\u2010Report\u20102015_FINAL.pdf(last accessed 29 July 2017)."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.8.6.547"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.049601"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.96"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.027706"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425250903393752"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e328328d577"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl399"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101050-00011"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.fpc.0000230413.97596.fa"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-7-32"},{"key":"e_1_2_7_22_1","unstructured":"ChouM BertrandJ BorandL VerstuyftC LaureillardD BlancFX.Pharmacokinetics of efavirenz in combination with rifampicin in HIV\u2010infected adults: results of the PECAN (ANRS 121454) study. 13th IntWorkshop on ClinPharmacology of HIV pharmacology 2012."},{"key":"e_1_2_7_23_1","unstructured":"World Health Organization.Treatment of tuberculosis guidelines2016. 4th Available athttp:\/\/apps.who.int\/iris\/bitstream\/10665\/44165\/1\/9789241547833_eng.pdf(last accessed 30 July 2017)."},{"key":"e_1_2_7_24_1","unstructured":"World Health Organisation.Treatment of tuberculosis guidelines. Geneva: 2010 Fourth Edition."},{"key":"e_1_2_7_25_1","unstructured":"World Health Organization.Treatment of tuberculosis: guidelines for treatment of drug\u2010susceptible tuberculosis and patient care2017 29th July 2017. Available from:http:\/\/apps.who.int\/iris\/bitstream\/10665\/255052\/1\/9789241550000\u2010eng.pdf?ua=1."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17141-9"},{"key":"e_1_2_7_27_1","first-page":"796","article-title":"Role of individual drugs in the chemotherapy of tuberculosis","volume":"4","author":"Mitchison DA","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2787(67)90147-5"},{"key":"e_1_2_7_29_1","doi-asserted-by":"crossref","first-page":"14478","DOI":"10.1016\/S0021-9258(18)98711-9","article-title":"RpoB8, a rifampicin\u2010resistant termination\u2010proficient RNA polymerase, has an increased km for purine nucleotides during transcription elongation","volume":"266","author":"Jin DJ","year":"1991","journal-title":"J Biol Chem"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00286-0"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103293441307"},{"key":"e_1_2_7_32_1","unstructured":"Sustiva (efavirenz) highlights of prescribing information.http:\/\/packageinsertsbms com\/pi\/pi_sustiva pdf 12 A.D. March 4. Available from:http:\/\/packageinserts.bms.com\/pi\/pi_sustiva.pdf."},{"key":"e_1_2_7_33_1","unstructured":"World Health Organization.Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 rev. 2010."},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1086\/505210"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000196181.18916.9b"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1780"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000183519.45137.a6"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-001-0396-3"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328360dbb4"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1166-5"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit466"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30482-6"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008315308"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2013.00024"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200107000-00004"},{"key":"e_1_2_7_46_1","unstructured":"World Health Organization.Use of high burden country lists for TB by WHO in the post\u20102015 era. Geneva2015. Available athttp:\/\/www.who.int\/tb\/publications\/global_report\/high_tb_burdencountrylists2016\u20102020.pdf?ua=1(last accessed 15 August 2017)."},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12403"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix248"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027810"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-7-8"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2413"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31819c33a3"},{"key":"e_1_2_7_54_1","first-page":"955","article-title":"Lack of association between plasma levels of non\u2010nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co\u2010administration in HIV\u2010infected TB patients","volume":"138","author":"Ramachandran G","year":"2013","journal-title":"Indian J Med Res"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.129"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-261"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.14.73"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02023-12"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1086\/599114"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit246"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.15.35"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2877"},{"key":"e_1_2_7_63_1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/135965350901400502","article-title":"Effect of rifampicin\u2010based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa","volume":"14","author":"Cohen K","year":"2009","journal-title":"Antivir Ther"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090350"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.11.011"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku348"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2483"},{"key":"e_1_2_7_68_1","first-page":"10","article-title":"Efavirenz plasma concentrations and HIV viral load in HIV\/AIDS\u2010tuberculosis infection patients treated with rifampicin","volume":"48","author":"Mariana N","year":"2016","journal-title":"Acta Med Indones"},{"key":"e_1_2_7_69_1","unstructured":"Sustiva.US Prescrition 2004. Princeton NJ: Bristol\u2010Myer Squibb;1998. 2004."},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ155"},{"issue":"1","key":"e_1_2_7_71_1","first-page":"S63","article-title":"Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome","volume":"196","author":"Helen M","year":"2007","journal-title":"J Infect Dis"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.3109\/03602532.2014.982864"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.160"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1101\/gr.103341.109"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-015-0004-2"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.2174\/1875692111201010043"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088497"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.156"},{"key":"e_1_2_7_79_1","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS Clinical Trials Group study","volume":"18","author":"Haas DW","year":"2004","journal-title":"AIDS"},{"key":"e_1_2_7_80_1","first-page":"237","article-title":"Neuropsychiatric manifestations of HIV infection and AIDS","volume":"30","author":"Dube B","year":"2005","journal-title":"J Psychiatry Neurosci"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.5.725"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000238"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu429"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318276cda9"},{"key":"e_1_2_7_85_1","unstructured":"CerroneM WangX NearyM WeaverC FedeleS Day\u2010WeberI et al. eds.Pharmacokinetics of efavirenz 400mg with isoniazid\/rifampicin in people with HIV. Conference on Retroviruses and Opportunistic Infections (CROI)[Abstract Number 457]; 2018 March 4\u20137 2018; Boston Massachusetts."},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.15.0577"},{"key":"e_1_2_7_87_1","unstructured":"AtwineD BaudinE Gel\u00e9T MuyindikeW KennethM KyohairweR et al. eds.Efavirenz pharmacokinetics with high\u2010dose rifampin in TB\u2010HIV infected patients. Conference on retroviruses and opportunistic infections (CROI) [Abstract number 456]; 2018 March 4\u20137 2018; Boston Massachusetts"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13600","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T14:56:38Z","timestamp":1694962598000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,22]]},"references-count":86,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1111\/bcp.13600"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13600","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,22]]}}}